Albireo Pharma Stock News

The stock price of Albireo Pharma Inc (NASDAQ: ALBO) increased by 1.55% in the most recent trading session. This is why it happened.

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in p

Wall Street brokerages forecast that Albireo Pharma, Inc. (NASDAQ:ALBO) will post earnings of ($1.39) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Albireo Pharmas earnings, with estimates ranging from ($2.11) to ($0.93). Albireo Pharma posted earnings per share of ($1.30) in the same quarter last year, []

Wedbush reissued their buy rating on shares of Albireo Pharma (NASDAQ:ALBO) in a report released on Monday morning, PriceTargets.com reports. The brokerage currently has a $84.00 price target on the biopharmaceutical companys stock. A number of other equities analysts also recently commented on ALBO. Robert W. Baird restated a buy rating and issued a $72.00 []

Chicago Capital LLC boosted its stake in shares of Albireo Pharma, Inc. (NASDAQ:ALBO) by 17.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 819,738 shares of the biopharmaceutical company’s stock after acquiring an additional 122,502 shares during the period. Chicago Capital LLC’s holdings in Albireo Pharma were worth $25,576,000 as of its most […]

BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year after almost three and a half years with the Company. Jan Mattsson, Ph.D., Chief Scientific Officer and co-founder of Albireo, will be taking over as the interim head of R&D, leading research and development of early and late-stage assets and programs. As one of the co-founders of the Company with deep experience in drug development and approvals, Dr. Mattsson is primed to lead the R&D organization with his institutional knowledge, vision for the pipeline and products, and ability to deliver against corporate objectives.

Equities analysts forecast that Albireo Pharma, Inc. (NASDAQ:ALBO) will announce $5.08 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Albireo Pharmas earnings, with the lowest sales estimate coming in at $3.58 million and the highest estimate coming in at $5.88 million. Albireo Pharma reported sales []

Metropolitan Life Insurance Co NY boosted its holdings in shares of Albireo Pharma, Inc. (NASDAQ:ALBO) by 90,960.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,553 shares of the biopharmaceutical companys stock after acquiring an additional 4,548 shares during []

Albireo developed Odevixibat - a product as a pipeline - as a life-saving therapy for multiple ultra-rare pediatric liver disease indications.

Shares of Albireo Pharma, Inc. (NASDAQ:ALBO) have been given a consensus recommendation of Buy by the six research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price target among []

Albireo Pharma, Inc. (NASDAQ:ALBO) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $27.16 and last traded at $27.32, with a volume of 784 shares changing hands. The stock had previously closed at $27.75. A number of equities research analysts recently commented on ALBO shares. Zacks []

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2021 Results - Earnings Call Transcript

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -333.33% and -83.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

— Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —